Chris JacobsSell
Anavex Life Sciences Corp. · Transaction Dec 12, 2022 · Filed Jan 20, 2023 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · AVXL
+0.64% · +$0.0100 · Vol 1.5M
Market closed · last close 4:00 PM ET · price as of 18:20:58 ET
Anavex Life Sciences Corp
Biotechnology
$1.54
Follow $AVXL
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $AVXL by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredThu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET · AVXL
MethodologyAVXL
Anavex Life Sciences Corp
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Lower range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
38/ 100
Veridion Score
Lower range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is AVXL moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Anavex Life Sciences Corp
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Listed since
2006
Employees
34
Country
US
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$1.53
Day high
$1.58
Day low
$1.50
Previous close
$1.53
52W high
$9.52
-83.83% from high
52W low
$1.50
0% of range
Market cap
$141.8M
EPS
$-0.1516
Beta
1.63
Shares out
92.7M
Volume
1.5M
1.46× rel vol
Avg volume
1M
VWAP
$1.54
Price history computed in-house
1W
-15.40%
1M
-44.01%
3M
-38.41%
1Y
-83.83%
YTD
-56.75%
SMA 50 $2.73 · below
SMA 200 $3.30 · below
52W position 0%
AVXL overview
Related filings and maps
Public disclosures
Congress activity in AVXL
1 filers · 1 buys · 1 sells (0 labeled S (partial)) · Oct 12, 2022 to Dec 12, 2022 · House 2 / Senate 0
All available history · Latest 2 of 2 lines · Read 2026-10-09T03:11:58.319Z
Official filing ↗
Chris JacobsBuy
Anavex Life Sciences Corp. · Transaction Oct 12, 2022 · Filed Nov 16, 2022 · $1,001 to $15,000
Federal contracts
AVXL contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for AVXL in this window.
Lobbying spend
AVXL lobbying filings, year to date.
Registered lobbying filings matched to Anavex Life Sciences Corp.
$100.0K
Refresh interval: 12hSource: LDA disclosure filings
Health Issues
Filing
$60.0K
ANAVEX LIFE SCIENCES
FORBES-TATE
Jan 18, 2026
Filing
$40.0K
ANAVEX LIFE SCIENCES
FORBES-TATE
Apr 17, 2026
Analyst ratings
Sovereign unlock shows live analyst consensus for AVXL.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.